Reduced SMAD7 leads to overactivation of TGF-β signaling in MDS that can be reversed by a specific inhibitor of TGF-β receptor I kinase

Li Zhou, Christine McMahon, Tushar Bhagat, Cristina Alencar, Yiting Yu, Melissa Fazzari, Davendra Sohal, Christoph Heuck, Krishna Gundabolu, Chun Ng, Yongkai Mo, Wa Shen, Amittha Wickrema, Guanghui Kong, Ellen Friedman, Lubomir Sokol, Giannis Mantzaris, Andrea Pellagatti, Jacqueline Boultwood, Leonidas C. PlataniasUlrich Steidl, Lei Yan, Jonathan M. Yingling, Michael M. Lahn, Alan List, Markus Bitzer, Amit Verma

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Even though myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, the molecular alterations that lead to marrow failure have not been well elucidated. We have previously shown that the myelosuppressive TGF-β pathway is constitutively activated in MDS progenitors. Because there is conflicting data about upregulation of extracellular TGF-β levels in MDS, we wanted to determine the molecular basis of TGF-β pathway overactivation and consequent hematopoietic suppression in this disease. We observed that SMAD7, a negative regulator of TGF-β receptor I (TBRI) kinase, is markedly decreased in a large meta-analysis of gene expression studies from MDS marrow-derived CD34 + cells. SMAD7 protein was also found to be significantly decreased in MDS marrow progenitors when examined immunohistochemically in a bone marrow tissue microarray. Reduced expression of SMAD7 in hematopoietic cells led to increased TGF-β-mediated gene transcription and enhanced sensitivity to TGF-β-mediated suppressive effects. The increased TGF-β signaling due to SMAD7 reduction could be effectively inhibited by a novel clinically relevant TBRI (ALK5 kinase) inhibitor, LY-2157299. LY-2157299 could inhibit TGF-β-mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells. Furthermore, in vivo administration of LY-2157299 ameliorated anemia in a TGF-β overexpressing transgenic mouse model of bone marrow failure. Most importantly, treatment with LY-2157199 stimulated hematopoiesis from primary MDS bone marrow specimens. These studies demonstrate that reduction in SMAD7 is a novel molecular alteration in MDS that leads to ineffective hematopoiesis by activating of TGF-β signaling in hematopoietic cells. These studies also illustrate the therapeutic potential of TBRI inhibitors in MDS.

Original languageEnglish (US)
Pages (from-to)955-963
Number of pages9
JournalCancer Research
Volume71
Issue number3
DOIs
StatePublished - Feb 1 2011

Fingerprint

Myelodysplastic Syndromes
LY-2157299
Phosphotransferases
Bone Marrow
Hematopoiesis
Hematopoietic Stem Cells
Transgenic Mice
Meta-Analysis
Anemia
Up-Regulation
Gene Expression
Bone and Bones
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Reduced SMAD7 leads to overactivation of TGF-β signaling in MDS that can be reversed by a specific inhibitor of TGF-β receptor I kinase. / Zhou, Li; McMahon, Christine; Bhagat, Tushar; Alencar, Cristina; Yu, Yiting; Fazzari, Melissa; Sohal, Davendra; Heuck, Christoph; Gundabolu, Krishna; Ng, Chun; Mo, Yongkai; Shen, Wa; Wickrema, Amittha; Kong, Guanghui; Friedman, Ellen; Sokol, Lubomir; Mantzaris, Giannis; Pellagatti, Andrea; Boultwood, Jacqueline; Platanias, Leonidas C.; Steidl, Ulrich; Yan, Lei; Yingling, Jonathan M.; Lahn, Michael M.; List, Alan; Bitzer, Markus; Verma, Amit.

In: Cancer Research, Vol. 71, No. 3, 01.02.2011, p. 955-963.

Research output: Contribution to journalArticle

Zhou, L, McMahon, C, Bhagat, T, Alencar, C, Yu, Y, Fazzari, M, Sohal, D, Heuck, C, Gundabolu, K, Ng, C, Mo, Y, Shen, W, Wickrema, A, Kong, G, Friedman, E, Sokol, L, Mantzaris, G, Pellagatti, A, Boultwood, J, Platanias, LC, Steidl, U, Yan, L, Yingling, JM, Lahn, MM, List, A, Bitzer, M & Verma, A 2011, 'Reduced SMAD7 leads to overactivation of TGF-β signaling in MDS that can be reversed by a specific inhibitor of TGF-β receptor I kinase', Cancer Research, vol. 71, no. 3, pp. 955-963. https://doi.org/10.1158/0008-5472.CAN-10-2933
Zhou, Li ; McMahon, Christine ; Bhagat, Tushar ; Alencar, Cristina ; Yu, Yiting ; Fazzari, Melissa ; Sohal, Davendra ; Heuck, Christoph ; Gundabolu, Krishna ; Ng, Chun ; Mo, Yongkai ; Shen, Wa ; Wickrema, Amittha ; Kong, Guanghui ; Friedman, Ellen ; Sokol, Lubomir ; Mantzaris, Giannis ; Pellagatti, Andrea ; Boultwood, Jacqueline ; Platanias, Leonidas C. ; Steidl, Ulrich ; Yan, Lei ; Yingling, Jonathan M. ; Lahn, Michael M. ; List, Alan ; Bitzer, Markus ; Verma, Amit. / Reduced SMAD7 leads to overactivation of TGF-β signaling in MDS that can be reversed by a specific inhibitor of TGF-β receptor I kinase. In: Cancer Research. 2011 ; Vol. 71, No. 3. pp. 955-963.
@article{09168b8172794db180e448e020a79762,
title = "Reduced SMAD7 leads to overactivation of TGF-β signaling in MDS that can be reversed by a specific inhibitor of TGF-β receptor I kinase",
abstract = "Even though myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, the molecular alterations that lead to marrow failure have not been well elucidated. We have previously shown that the myelosuppressive TGF-β pathway is constitutively activated in MDS progenitors. Because there is conflicting data about upregulation of extracellular TGF-β levels in MDS, we wanted to determine the molecular basis of TGF-β pathway overactivation and consequent hematopoietic suppression in this disease. We observed that SMAD7, a negative regulator of TGF-β receptor I (TBRI) kinase, is markedly decreased in a large meta-analysis of gene expression studies from MDS marrow-derived CD34 + cells. SMAD7 protein was also found to be significantly decreased in MDS marrow progenitors when examined immunohistochemically in a bone marrow tissue microarray. Reduced expression of SMAD7 in hematopoietic cells led to increased TGF-β-mediated gene transcription and enhanced sensitivity to TGF-β-mediated suppressive effects. The increased TGF-β signaling due to SMAD7 reduction could be effectively inhibited by a novel clinically relevant TBRI (ALK5 kinase) inhibitor, LY-2157299. LY-2157299 could inhibit TGF-β-mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells. Furthermore, in vivo administration of LY-2157299 ameliorated anemia in a TGF-β overexpressing transgenic mouse model of bone marrow failure. Most importantly, treatment with LY-2157199 stimulated hematopoiesis from primary MDS bone marrow specimens. These studies demonstrate that reduction in SMAD7 is a novel molecular alteration in MDS that leads to ineffective hematopoiesis by activating of TGF-β signaling in hematopoietic cells. These studies also illustrate the therapeutic potential of TBRI inhibitors in MDS.",
author = "Li Zhou and Christine McMahon and Tushar Bhagat and Cristina Alencar and Yiting Yu and Melissa Fazzari and Davendra Sohal and Christoph Heuck and Krishna Gundabolu and Chun Ng and Yongkai Mo and Wa Shen and Amittha Wickrema and Guanghui Kong and Ellen Friedman and Lubomir Sokol and Giannis Mantzaris and Andrea Pellagatti and Jacqueline Boultwood and Platanias, {Leonidas C.} and Ulrich Steidl and Lei Yan and Yingling, {Jonathan M.} and Lahn, {Michael M.} and Alan List and Markus Bitzer and Amit Verma",
year = "2011",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-10-2933",
language = "English (US)",
volume = "71",
pages = "955--963",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Reduced SMAD7 leads to overactivation of TGF-β signaling in MDS that can be reversed by a specific inhibitor of TGF-β receptor I kinase

AU - Zhou, Li

AU - McMahon, Christine

AU - Bhagat, Tushar

AU - Alencar, Cristina

AU - Yu, Yiting

AU - Fazzari, Melissa

AU - Sohal, Davendra

AU - Heuck, Christoph

AU - Gundabolu, Krishna

AU - Ng, Chun

AU - Mo, Yongkai

AU - Shen, Wa

AU - Wickrema, Amittha

AU - Kong, Guanghui

AU - Friedman, Ellen

AU - Sokol, Lubomir

AU - Mantzaris, Giannis

AU - Pellagatti, Andrea

AU - Boultwood, Jacqueline

AU - Platanias, Leonidas C.

AU - Steidl, Ulrich

AU - Yan, Lei

AU - Yingling, Jonathan M.

AU - Lahn, Michael M.

AU - List, Alan

AU - Bitzer, Markus

AU - Verma, Amit

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Even though myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, the molecular alterations that lead to marrow failure have not been well elucidated. We have previously shown that the myelosuppressive TGF-β pathway is constitutively activated in MDS progenitors. Because there is conflicting data about upregulation of extracellular TGF-β levels in MDS, we wanted to determine the molecular basis of TGF-β pathway overactivation and consequent hematopoietic suppression in this disease. We observed that SMAD7, a negative regulator of TGF-β receptor I (TBRI) kinase, is markedly decreased in a large meta-analysis of gene expression studies from MDS marrow-derived CD34 + cells. SMAD7 protein was also found to be significantly decreased in MDS marrow progenitors when examined immunohistochemically in a bone marrow tissue microarray. Reduced expression of SMAD7 in hematopoietic cells led to increased TGF-β-mediated gene transcription and enhanced sensitivity to TGF-β-mediated suppressive effects. The increased TGF-β signaling due to SMAD7 reduction could be effectively inhibited by a novel clinically relevant TBRI (ALK5 kinase) inhibitor, LY-2157299. LY-2157299 could inhibit TGF-β-mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells. Furthermore, in vivo administration of LY-2157299 ameliorated anemia in a TGF-β overexpressing transgenic mouse model of bone marrow failure. Most importantly, treatment with LY-2157199 stimulated hematopoiesis from primary MDS bone marrow specimens. These studies demonstrate that reduction in SMAD7 is a novel molecular alteration in MDS that leads to ineffective hematopoiesis by activating of TGF-β signaling in hematopoietic cells. These studies also illustrate the therapeutic potential of TBRI inhibitors in MDS.

AB - Even though myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, the molecular alterations that lead to marrow failure have not been well elucidated. We have previously shown that the myelosuppressive TGF-β pathway is constitutively activated in MDS progenitors. Because there is conflicting data about upregulation of extracellular TGF-β levels in MDS, we wanted to determine the molecular basis of TGF-β pathway overactivation and consequent hematopoietic suppression in this disease. We observed that SMAD7, a negative regulator of TGF-β receptor I (TBRI) kinase, is markedly decreased in a large meta-analysis of gene expression studies from MDS marrow-derived CD34 + cells. SMAD7 protein was also found to be significantly decreased in MDS marrow progenitors when examined immunohistochemically in a bone marrow tissue microarray. Reduced expression of SMAD7 in hematopoietic cells led to increased TGF-β-mediated gene transcription and enhanced sensitivity to TGF-β-mediated suppressive effects. The increased TGF-β signaling due to SMAD7 reduction could be effectively inhibited by a novel clinically relevant TBRI (ALK5 kinase) inhibitor, LY-2157299. LY-2157299 could inhibit TGF-β-mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells. Furthermore, in vivo administration of LY-2157299 ameliorated anemia in a TGF-β overexpressing transgenic mouse model of bone marrow failure. Most importantly, treatment with LY-2157199 stimulated hematopoiesis from primary MDS bone marrow specimens. These studies demonstrate that reduction in SMAD7 is a novel molecular alteration in MDS that leads to ineffective hematopoiesis by activating of TGF-β signaling in hematopoietic cells. These studies also illustrate the therapeutic potential of TBRI inhibitors in MDS.

UR - http://www.scopus.com/inward/record.url?scp=79551518231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551518231&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-2933

DO - 10.1158/0008-5472.CAN-10-2933

M3 - Article

C2 - 21189329

AN - SCOPUS:79551518231

VL - 71

SP - 955

EP - 963

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 3

ER -